Navigation Links
Cinryze® (C1 Esterase Inhibitor [Human]) Data Presented at 2010 International Scientific Conference of the World Allergy Organization (WAO)
Date:12/6/2010

ed as unequivocal relief or the presence of one or two consecutive 15 minute assessments consistent with improvement immediately prior to discharge, occurred in 73 percent of attacks within one hour, and 95 percent within four hours;
  • 65 percent of laryngeal attacks achieved unequivocal relief or at least one report consistent with improvement immediately prior to discharge within one hour, and 90 percent within four hours;
  • Of the 84 laryngeal attacks, none required intubation after the receipt of Cinryze;
  • Responses to Cinryze in subjects with more than one attack did not diminish with subsequent repeated administration;
  • Infusion site pain, joint swelling, rash, and sinusitis were reported as treatment-emergent Cinryze-related adverse events.  

  • In a poster entitled, "Open-Label Use of Nanofiltered C1 Esterase Inhibitor (Human) (nf-C1 INH) for Treatment of Acute Attacks of Hereditary Angioedema (HAE) in Pediatric Subjects,' Dr. Timothy Craig, M.D. of the Hershey Medical Center in Harrisburg, PA, presented open label experience with Cinryze in treating 121 HAE attacks in 22 pediatric patients with HAE. Data from this study included the following:

    • The overall median time to beginning of relief of all attacks was 15 minutes;
    • Overall response rates within 4 hours were 89 to 97 percent for unequivocal relief and clinical relief, respectively;
    • No subjects with a laryngeal attack required intubation;
    • In subjects who were treated for multiple attacks, repeated therapy with Cinryze did not diminish the response to treatment;
    • Of the 121 acute attacks treated with Cinryze, 88 attacks were treated with one dose of Cinryze; 33 attacks required two doses;
    • There were no serious adverse events, and no adverse events were considered related to Cinryze.  No subject discontinued study drug due to an adverse event;  
    • There was no evid
      '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
    2. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
    3. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
    4. Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care
    5. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
    6. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
    7. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
    8. Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765
    9. Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting
    10. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
    11. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... , Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: ... immune therapies for operable and inoperable solid tumor cancers, announced ... the 7 th Annual Phacilitate Immunotherapy Forum in ... at Phacilitate will take place on January 26 at 10:30 ...
    (Date:1/23/2015)... , Jan. 23, 2015 More than a third ... quarter of those with private insurance, filled a prescription for ... a report in this week,s Morbidity and Mortality Weekly Report ... care providers to treat moderate to severe pain.  They are ...
    (Date:1/23/2015)... 2015 /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is investigating ... Inc. ("Advaxis" or the "Company") (NASDAQ: ADXS ... duties to shareholders. On January 21, 2015, ... that Advaxis had misrepresented the clinical data for its ...
    Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
    (Date:1/23/2015)... 2015 Hastings and Hastings, a law firm ... record number of legal representation client review requests for slip ... a steady rise in the number of slip and fall ... throughout the Valley. With that said, a large number of ... an experienced law firm. Hastings and Hastings is a personal ...
    (Date:1/22/2015)... 22, 2015 The City of West Hollywood hosted ... to commemorate the 42nd anniversary of the Supreme Court decision Roe ... been 42 years since the Roe vs. Wade decision and the ... present as ever,” said City of West Hollywood Councilmember Abbe Land. ...
    (Date:1/22/2015)... The Incredible Bulk is a revolutionary method put together ... by up to 30lbs in less than 12 weeks without ... Stevenson, prompting an investigative review. , “Our Incredible Bulk ... formula that allows the body to pack on a massive ...
    (Date:1/22/2015)... Florida (PRWEB) January 22, 2015 Juvent ... today at the 2015 PGA Merchandise Show to bestow ... and incredible female amateur golfer, Arlene McKitrick. The award ... female amateur golf tournament win. She won her first ...
    (Date:1/22/2015)... January 22, 2015 Carinsurancesavings.biz has released a ... death and dismemberment insurance . , Purchasing an accidental ... be very advantageous. This type of rider provides benefits if ... can be considered a lesser form of life insurance. ...
    Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
    ... are becoming common everywhere. Only last fortnight it was reported ... 15 ft during a joyride and sustained grievous injuries in ... ,But for a tree branch which checked her ... first aid facilities available, it was reported. ,Now ...
    ... with Delmont Laboratory to introduce its immunotherapeutic vaccine Staphage ... to this initial agreement, Delmont Laboratory will supply bulk ... the final packaging in China. ,CBPC will ... to be signed. This product requires a clinical study ...
    ... fill their prescriptions while traveling abroad need to be cautious ... the AAPS National Biotechnology Conference. ,Unlike approved ... internationally. Therefore, consumers should not assume that a branded product ... the same or similar brand name in other counties. ...
    ... seven billion dollar (5.2 billion euro) negligence suit against ... as the US giant demanded the charges be ... early setback when the court rejected a request to ... Babs Kwewumi adjourned the trial to July 20. ...
    ... announces that it has completed its acquisition of ... for approximately $600 million on April 4, 2007. ... owns the patents for Electrochemiluminescence (ECL) technology and ... diagnostics field into new market segments such as ...
    ... called the world's first prototype of an artificial hand with ... up a raw egg. ,Squse, a Kyoto-based ... 400-gramme (14 ounce) hand with five human-sized fingers with artificial ... ,"So far, robots have an image of helping people do ...
    Cached Medicine News:Health News:Girls Feet Severed in Amusement Park Accident 2Health News:Nigeria Launches Seven Billion Dollar Case Against Pfizer 2Health News:Nigeria Launches Seven Billion Dollar Case Against Pfizer 3
    ... Webster is the source for a complete ... catheters for left-sided mapping - all with ... come to expect from the leader in ... sinus diagnostic catheters are specifically designed and ...
    4Fr, 5Fr & 6Fr diagnostic electrophysiology catheters with fixed curves....
    ... Mennen Medical offers patient monitoring ... high acuity and medium acuity monitoring. ... premier monitoring product. The Enmove ... monitoring solution to complement the Envoy. ...
    ... Advanced engineering, rapid acquisition of ... make it the most accurate autorefractor ... inch High Quality Monitor allows for ... readings are taken as soon as ...
    Medicine Products: